Evidence map›Paper›PMID 35590248›Full record

ArticleClinical proteomics2022

Santosh Renuse, Linda M Benson, Patrick M Vanderboom, F N U Ruchi, Yogesh R Yadav, Kenneth L Johnson, Benjamin C Brown, Jane A Peterson, Rita Basu, Daniel J McCormick and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Santosh RenuseDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First ST SW, Rochester, MN, 55905, USA.
Linda M BensonMayo Genomics Facility-Proteomics Core, Mayo Clinic, Rochester, MN, 55905, USA.
Patrick M VanderboomDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First ST SW, Rochester, MN, 55905, USA.
F N U RuchiDivision of Endocrinology, Center of Diabetes Technology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA.
Yogesh R YadavDivision of Endocrinology, Center of Diabetes Technology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA.
Kenneth L JohnsonMayo Genomics Facility-Proteomics Core, Mayo Clinic, Rochester, MN, 55905, USA.
Benjamin C BrownMayo Genomics Facility-Proteomics Core, Mayo Clinic, Rochester, MN, 55905, USA.
Jane A PetersonMayo Genomics Facility-Proteomics Core, Mayo Clinic, Rochester, MN, 55905, USA.
Rita BasuDivision of Endocrinology, Center of Diabetes Technology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA.
Daniel J McCormickDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905, USA.
Akhilesh PandeyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First ST SW, Rochester, MN, 55905, USA. pandey.akhilesh@mayo.edu.ORCID http://orcid.org/0000-0001-9943-6127
Ananda BasuDivision of Endocrinology, Center of Diabetes Technology, University of Virginia School of Medicine, Charlottesville, VA, 22903, USA. AB8YN@hscmail.mcc.virginia.edu.
Mayo Clinic · USMayo Clinic in Arizona · USUniversity of Virginia · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2013 to 2026
$19.5M
MECHANISMS OF INSULIN RESISTANCE IN MANR01DK029953 · NIDDK · UNIVERSITY OF VIRGINIA · PI BASU, RITA · 1986 to 2024
$11.5M
Integrated Approaches to Close the Loop in Type 1 DiabetesR01DK085516 · NIDDK · UNIVERSITY OF VIRGINIA · PI BASU, ANANDA · 2009 to 2021
$6.5M
NIDDK NIH HHS P30 DK079626NIDDK NIH HHS R01 DK029953NIDDK NIH HHS R01 DK085516
6 · The paper itself

Abstract

backgroundGlucagon serves as an important regulatory hormone for regulating blood glucose concentration with tight feedback control exerted by insulin and glucose. There are critical gaps in our understanding of glucagon kinetics, pancreatic α cell function and intra-islet feedback network that are disrupted in type 1 diabetes. This is important for translational research applications of evolving dual-hormone (insulin + glucagon) closed-loop artificial pancreas algorithms and their usage in type 1 diabetes. Thus, it is important to accurately measure glucagon kinetics in vivo and to develop robust models of glucose-insulin-glucagon interplay that could inform next generation of artificial pancreas algorithms.

methodsHere, we describe the administration of novel

resultsThe limit of quantitation was found to be 1.56 pg/ml using stable isotope-labeled glucagon as an internal standard. Intra and inter-assay variability was < 6% and < 16%, respectively, for FF glucagon while it was < 5% and < 23%, respectively, for FFLA glucagon. Further, we carried out a novel isotope dilution technique using glucagon tracers for studying glucagon kinetics in type 1 diabetes.

conclusionsThe methods described in this study for simultaneous detection and quantitation of glucagon tracers have clinical utility for investigating glucagon kinetics in vivo in humans.

Indexed as

InsulinOral glucose tolerance testStable isotope tracersType 1 diabetes

Identifiers

PMID35590248
PMCPMC9118570
OpenAlexW4280494470

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.